Ronald W. Barrett
Director/Board Member chez JANUX THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Ronald W.
Barrett was the founder of XenoPort, Inc. (founded in 1999) where he served as the Chief Executive Officer & Director from 2001 to 2015.
He is currently the Chairman & Chief Executive Officer at Medikine, Inc. since 2016.
Dr. Barrett is also a Director at Quadriga BioSciences, Inc. and Janux Therapeutics, Inc. Dr. Barrett previously held the position of Independent Director at Concert Pharmaceuticals, Inc. from 2007 to 2022.
He also worked as a Principal at Abbott Laboratories from 1986 to 1989 and as the Senior Vice President-Research at Affymax Research Institute from 1989 to 1999.
Dr. Barrett obtained his undergraduate degree from Bucknell University and his doctorate degree from Rutgers State University of New Jersey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC.
-.--% | 14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Ronald W. Barrett
| Sociétés | Poste | Début |
|---|---|---|
| JANUX THERAPEUTICS, INC. | Director/Board Member | 07/09/2021 |
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Chief Executive Officer | 01/06/2017 |
Quadriga BioSciences, Inc.
 Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Director/Board Member | - |
Anciens postes connus de Ronald W. Barrett
| Sociétés | Poste | Fin |
|---|---|---|
| CONCERT PHARMACEUTICALS, INC. | Director/Board Member | 09/06/2022 |
| XENOPORT, INC. | Chief Executive Officer | 29/09/2015 |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Chief Tech/Sci/R&D Officer | 01/01/1999 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/1989 |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Director/Board Member | - |
Formation de Ronald W. Barrett
| Bucknell University | Undergraduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| JANUX THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Concert Pharmaceuticals, Inc.
 Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | Health Technology |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Health Technology |
